CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 444 filers reported holding CRISPR THERAPEUTICS AG in Q1 2022. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,217 | -54.9% | 159 | -44.2% | 0.00% | -33.3% |
| Q2 2023 | $16,000 | +61.5% | 285 | +30.1% | 0.00% | 0.0% |
| Q1 2023 | $9,905 | -81.5% | 219 | -83.3% | 0.00% | -81.2% |
| Q4 2022 | $53,455 | -69.5% | 1,315 | -54.2% | 0.02% | -66.7% |
| Q2 2022 | $175,000 | +133.3% | 2,873 | +141.8% | 0.05% | +152.6% |
| Q1 2022 | $75,000 | +25.0% | 1,188 | +49.2% | 0.02% | +26.7% |
| Q4 2021 | $60,000 | +150.0% | 796 | +277.3% | 0.02% | +50.0% |
| Q3 2021 | $24,000 | -73.0% | 211 | -61.6% | 0.01% | -61.5% |
| Q2 2021 | $89,000 | +27.1% | 550 | -4.3% | 0.03% | +8.3% |
| Q1 2021 | $70,000 | – | 575 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |